KR20220165267A - 항-cd6 항체 조성물 및 covid-19를 포함하는 코로나 바이러스의 부정적인 영향의 치료 및 감소 방법 - Google Patents

항-cd6 항체 조성물 및 covid-19를 포함하는 코로나 바이러스의 부정적인 영향의 치료 및 감소 방법 Download PDF

Info

Publication number
KR20220165267A
KR20220165267A KR1020227038692A KR20227038692A KR20220165267A KR 20220165267 A KR20220165267 A KR 20220165267A KR 1020227038692 A KR1020227038692 A KR 1020227038692A KR 20227038692 A KR20227038692 A KR 20227038692A KR 20220165267 A KR20220165267 A KR 20220165267A
Authority
KR
South Korea
Prior art keywords
antibody
seq
covid
patients
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038692A
Other languages
English (en)
Korean (ko)
Inventor
프라딥 나일
호세 엔리께 몬테로 카시미로
키란 마줌다쇼
우샤 부가니
샌디프 닐칸스 아탈리
메랄코드 수바라만 라마크리샨
타니아 크롬벳 라모스
칼렛 레온 몬존
마이라 라모스 수자르트
Original Assignee
바이오콘 리미티드
센트로 데 인뮤놀러지아 모레큘러
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by 바이오콘 리미티드, 센트로 데 인뮤놀러지아 모레큘러 filed Critical 바이오콘 리미티드
Publication of KR20220165267A publication Critical patent/KR20220165267A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227038692A 2020-04-04 2021-04-03 항-cd6 항체 조성물 및 covid-19를 포함하는 코로나 바이러스의 부정적인 영향의 치료 및 감소 방법 Pending KR20220165267A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
CUCU-2020-0027 2020-04-17
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
KR20220165267A true KR20220165267A (ko) 2022-12-14

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038692A Pending KR20220165267A (ko) 2020-04-04 2021-04-03 항-cd6 항체 조성물 및 covid-19를 포함하는 코로나 바이러스의 부정적인 영향의 치료 및 감소 방법

Country Status (15)

Country Link
US (1) US20230151107A1 (https=)
EP (1) EP4126961A4 (https=)
JP (1) JP2023526890A (https=)
KR (1) KR20220165267A (https=)
CN (1) CN115698071A (https=)
AU (1) AU2021247258A1 (https=)
BR (1) BR112022018936A2 (https=)
CA (1) CA3174566A1 (https=)
CL (1) CL2022002684A1 (https=)
CO (1) CO2022014199A2 (https=)
IL (1) IL296487A (https=)
MX (1) MX2022012229A (https=)
TW (1) TW202200202A (https=)
WO (1) WO2021199006A1 (https=)
ZA (1) ZA202210032B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
JP7065085B2 (ja) * 2016-10-18 2022-05-11 バイオコン・リミテッド Ｃｄ６のリン酸化を低減させるためのイトリズマブの使用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
KR20110112307A (ko) * 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
CN112424226B (zh) * 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
WO2021130195A1 (en) * 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Method of treating virus infection using a tlr7 agonist

Also Published As

Publication number Publication date
EP4126961A4 (en) 2024-07-17
TW202200202A (zh) 2022-01-01
MX2022012229A (es) 2022-10-27
CL2022002684A1 (es) 2023-03-24
US20230151107A1 (en) 2023-05-18
WO2021199006A1 (en) 2021-10-07
EP4126961A1 (en) 2023-02-08
ZA202210032B (en) 2024-09-25
AU2021247258A1 (en) 2022-11-10
JP2023526890A (ja) 2023-06-26
BR112022018936A2 (pt) 2022-12-06
IL296487A (en) 2022-11-01
CN115698071A (zh) 2023-02-03
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08

Similar Documents

Publication Publication Date Title
Zhang et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
KR20230005139A (ko) 코로나바이러스 감염 및 이로 인한 염증-유발된 폐 손상의 치료 방법
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
KR20220165267A (ko) 항-cd6 항체 조성물 및 covid-19를 포함하는 코로나 바이러스의 부정적인 영향의 치료 및 감소 방법
KR20240073720A (ko) Covid-19 질환을 치료하는 신규 조성물 및 방법
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
US8691752B2 (en) Protein product for treatment of infectious diseases and related inflammatory processes
KR20220139922A (ko) 인터페론 람다로의 코로나바이러스 감염의 치료
EP4137144A2 (en) Peptide for the treatment of cytokine storm syndrome
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2025527521A (ja) 急性呼吸不全の治療
Çolak et al. Efficacy of tocilizumab in severe COVID-19: a retrospective study
JP2023541921A (ja) Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果
RU2834279C1 (ru) Пептид для лечения синдрома цитокинового шторма
RU2837859C1 (ru) Лечение коронавирусной инфекции
EP4153310B1 (en) Bbeta-15-42 for the treatment of viral endothelitis
US20220184053A1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN118574633A (zh) 可溶性晚期糖基化终末产物受体蛋白用于预防或治疗肺部感染疾病的用途
WO2021202923A1 (en) Immunomodulator for the prevention and treatment of coronovirus infection and other conditions
JPWO2009028573A1 (ja) 血液凝固障害におけるリバビリンの利用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902